"Phylogica has also established a number of external collaborations which are aimed at providing
independent validation of the Phylomer platform as a delivery technology. In this context a
collaborator will use a Functional Penetrating Phylomer (FPP) to deliver their designated cargo (a
biologic drug) into the intracellular environment. A number of these collaborations are at a similar
stage of development to Phylogica’s internal program and are expected to begin providing data on
the efficacy of Phylomers as a delivery technology over the coming months."
Interesting "a collaborator" is just about to test delivery of a Fpp to deliver their cargo intra cellularly. Could this be genentech? Could this be someone else that could lead to a new deal??
I was a bit concerned when they stated they were concentrating on oncology. If their endosomal escape functionality was as good as they say it seemed to be limiting their opportunities. Good to see from this part of announcement that they are still working in other areas.
PYC Price at posting:
1.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)